Prabhat Singh | Pharmacology | Excellence in Research

Posted on by Forensic Scientist

Dr. Prabhat Singh | Neuroscience | Excellence in Research

Faculty of Pharmacy, Swami Vivekanand Subharti University | India

Dr. Prabhat Singh, a seasoned academic and researcher in the field of Pharmacology, currently serves as an Associate Professor at Kharvel Subharti College of Pharmacy, Swami Vivekanand Subharti University, Meerut. Born on July 8, 1988, Dr. Singh holds a B. Pharm., M. Pharm. (Pharmacology), and a Ph.D. His passion lies in advancing pharmaceutical education and scientific R&D. His academic dedication and research acumen have established him as a prominent figure in neuropharmacological research.

Professional profile👤

Google Scholar

ORCID

Scopus

Strengths for the Awards✨

Dr. Prabhat Singh demonstrates a consistent and impactful research trajectory in the field of Neuropharmacology, Vascular Dementia, and Physiological Brain Conditioning. With over 22 peer-reviewed publications, several in high-impact journals such as Neurochemical Research, Current Neurovascular Research, and Central Nervous System Agents in Medicinal Chemistry, his work reflects both depth and innovation.

  • He has published research with a total international impact factor exceeding 31.8, an h-index of 9, and over 300 citations, highlighting growing academic recognition.

  • His exploration of novel pharmacological targets in ischemia-reperfusion brain injury and morphine withdrawal syndromes represents translational value in therapeutic strategies.

  • Dr. Singh has contributed significantly to scholarly literature through book publications (4 authored books), book chapters (3 in Nova Science Publishers, USA), and 6 IPRs on innovative healthcare technologies, including AI-powered medication systems and neurodegenerative disease detection devices.

  • As a Ph.D. supervisor to six scholars and mentor to eight M.Pharm students, he has actively nurtured the next generation of pharmaceutical researchers.

🎓 Education

Dr. Singh completed his Ph.D. in Pharmacology from Dr. APJ Abdul Kalam Technical University, Lucknow in 2022. He earned his M. Pharm. from Mahamaya Technical University, Noida with an impressive 81.78% in 2013 and his B. Pharm. from Uttar Pradesh Technical University in 2011 with 73.19%. His foundational education was completed under the Uttar Pradesh Board, achieving consistent academic performance. He is also a GPAT qualifier (2011) and actively contributes to university committees.

👨‍🏫 Experience

Dr. Singh has over a decade of teaching experience. Since February 2023, he has been working as an Associate Professor at Kharvel Subharti College of Pharmacy. Previously, he served as Assistant Professor at the same institution from 2016 to 2023 and at Kalka Institute for Research and Advanced Studies from 2013 to 2016. Additionally, he has industrial experience as a Product Sales Representative with Dr. Reddy’s Laboratories. He has guided 08 M. Pharm theses and is currently supervising 06 Ph.D. scholars.

🔬 Research Interests On Pharmacology

Dr. Singh’s research interests are deeply rooted in Neuropharmacology, with specific focus on vascular dementia, neurotoxicity, and physiological brain conditioning. His doctoral research involved novel pharmacological interventions during experimental ischemia-reperfusion brain injury. His work integrates behavioral neuroscience and biochemical analysis to explore therapeutic pathways in brain disorders.

🏆 Awards & Achievements

Dr. Singh is a committed academic with a strong track record of publication and intellectual property. He has authored four books, contributed to multiple book chapters published by Nova Science Publishers, and published six IPRs including innovations in AI-based medication systems and neurodegenerative disease detection devices. His cumulative journal impact factor exceeds 31.8, with an h-index of 9 and over 300 citations.

đź“š Publications

  • Neuroprotective effects of agomelatine and vinpocetine against chronic cerebral hypoperfusion induced vascular dementia
    Authors: S Gupta, P Singh, B Mohan Sharma, B Sharma
    Year: 2015
    Citations: 73

  • Melatonin receptor and KATP channel modulation in experimental vascular dementia
    Authors: P Singh, S Gupta, B Sharma
    Year: 2015
    Citations: 45

  • Modulation of transient receptor potential vanilloid subtype 1 (TRPV1) and norepinephrine transporters (NET) protect against oxidative stress, cellular injury, and vascular …
    Authors: S Gupta, B Sharma, P Singh, B Mohan Sharma
    Year: 2014
    Citations: 40

  • Neuroprotective effects of nicorandil in chronic cerebral hypoperfusion-induced vascular dementia
    Authors: S Gupta, P Singh, B Sharma
    Year: 2016
    Citations: 26

  • Reversal in cognition impairments, cholinergic dysfunction, and cerebral oxidative stress through the modulation of ryanodine receptors (RyRs) and cysteinyl leukotriene-1 …
    Authors: P Singh, B Sharma
    Year: 2016
    Citations: 25

  • Selective serotonin-norepinephrine re-uptake inhibition limits renovascular-hypertension induced cognitive impairment, endothelial dysfunction, and oxidative stress injury
    Authors: P Singh, B Sharma
    Year: 2016
    Citations: 23

  • In vivo and in vitro attenuation of naloxone-precipitated experimental opioid withdrawal syndrome by insulin and selective KATP channel modulator
    Authors: P Singh, B Sharma, S Gupta, BM Sharma
    Year: 2015
    Citations: 22

  • Antiepileptic activity of aqueous extract of Tricosanthes dioica Roxb
    Authors: SG Prabhat Singh, Vipin K Garg, Pramod K Sharma
    Year: 2012
    Citations: 13

  • Plant bioactive compounds and their mechanistic approaches in the treatment of diabetes: a review
    Authors: Anshika, RK Pandey, L Singh, S Kumar, P Singh, M Pathak, S Jain
    Year: 2022
    Citations: 12

  • Antagonism of endothelin (ETA and ETB) receptors during renovascular hypertension-induced vascular dementia improves cognition
    Authors: P Singh, S Gupta, B Sharma
    Year: 2016
    Citations: 12

🧩 Conclusion

Dr. Prabhat Singh exemplifies academic excellence and research innovation in pharmacological sciences. With deep engagement in neuropharmacology, substantial teaching contributions, groundbreaking IPRs, and impactful publications, he continues to push the frontiers of pharmaceutical research and education. His commitment to scientific inquiry and student mentorship makes him a highly deserving candidate for this prestigious research award.

Qingbao Guo | Neuroscience | Outstanding Scientist Award

Posted on by Forensic Scientist

Prof. Qingbao Guo | Neuroscience | Outstanding Scientist Award

Xi’an No.9 Hospital | China

Prof. Qingbao Guo is a highly accomplished Associate Chief Physician in the Department of Neurosurgery at the Second Affiliated Hospital of the Air Force Medical University (formerly Tangdu Hospital), China. He specializes in cerebrovascular disorders, brain tumors, and functional neurosurgery, and is recognized for his excellence in the diagnosis and treatment of moyamoya disease and other complex neurological conditions.

Professional profile👤

ORCID

Scopus

Strengths for the Awards✨

  1. Extensive Clinical Experience:

    • Over 20 years of progressive clinical practice in neurosurgery, including leadership as Associate Chief Physician at a top-tier military hospital.

    • Strong surgical expertise in cerebrovascular diseases, brain tumors, and functional neurosurgery, which are critical areas in modern neurosurgical practice.

  2. Academic Qualifications & Research:

    • A recent Ph.D. in Neurosurgery (2021–2024) focused on moyamoya disease (MMD)—a rare but significant cerebrovascular disorder.

    • Earlier Master’s-level research on peripheral vascular diseases, showing continuity in vascular-focused research.

    • Mentorship under established experts (Professors Lian Duan and Yanzheng He), enhancing academic rigor.

  3. Contribution to National Defense Health System:

    • His long-term service in military medical institutions (Air Force Medical University) underscores contributions to military medicine, a high-impact field with national importance.

  4. Interdisciplinary Relevance:

    • His work bridges clinical practice and surgical innovation, especially in the surgical management of complex neurological diseases, offering translational value to both academic and applied medicine.

🎓 Education

Prof. Qingbao Guo began his academic journey with a Bachelor’s degree in Clinical Medicine from Yan’an University (1999–2004). He furthered his specialization with a Master’s degree in Surgery (2008–2011) from Southwest Medical University, under the supervision of Prof. Yanzheng He, where he focused on clinical approaches to peripheral vascular diseases. Most recently, he earned his Ph.D. in Neurosurgery (2021–2024) from the Chinese PLA Medical School, mentored by Prof. Lian Duan, with research concentrating on the pathogenesis and surgical management of moyamoya disease.

đź’Ľ Professional Experience

Prof. Qingbao Guo has an extensive and progressive professional background in neurosurgery. He is currently serving as an Associate Chief Physician at Tangdu Hospital since September 2012, where he has amassed advanced surgical experience in managing brain tumors, vascular pathologies, and functional neurosurgical disorders. Prior to this, he was an Attending Physician at the First Affiliated Hospital of Southwest Medical University (July 2011 – August 2012), where he handled numerous vascular cases. His medical career began as a Resident Physician at Shaanxi Sengong Hospital (July 2004 – August 2008).

🔬 Research Interests On Neuroscience

Prof. Qingbao Guo’s research focuses on the pathophysiology and surgical treatment of cerebrovascular diseases, particularly moyamoya disease, a rare but serious condition affecting intracranial arteries. He is also interested in neuro-oncology, vascular neurosurgery, and advancements in functional neurosurgical procedures, with a vision to bridge translational neuroscience and surgical innovation.

🏆 Awards & Nominations

Prof. Qingbao Guo has been acknowledged for his clinical excellence and academic contribution through multiple hospital-level and regional honors. He is a nominee for the [Insert Award Name Here, e.g., “Outstanding Neurosurgeon Researcher Award 2025”] in recognition of his pioneering work in moyamoya disease surgical treatment and his consistent commitment to patient-centered research and education.

đź“š Publications

🔬 Genetic Associations and Polymorphisms

  1. MTHFR Polymorphism and EDAS-induced Collateral Formation

    • [DOI: 10.3171/2024.1.JNS232121]
      Highlights the genetic influence (MTHFR) on surgical angiogenesis success post-EDAS in MMD patients.

  2. RNF213 p.R4810K Variant and Unfavorable Outcomes in Pediatric EDAS

    • [DOI: 10.1155/2024/1844190]
      Strong linkage of the RNF213 mutation with poor long-term outcomes, particularly relevant in East Asian populations.

🧪 Biomarker and Multi-Omics Studies

  1. Proteomic & Metabolomic Profiles in Pediatric MMD

    • [DOI: 10.2147/JIR.S471538]
      Identifies core disrupted pathways, potentially pointing toward new diagnostic or therapeutic targets.

  2. Complement C3 Expression & Postoperative Vasculopathy

    • [DOI: 10.2147/JIR.S451538]
      Suggests inflammatory markers like C3 as predictors of vascular changes post-intervention.

🧠 Neuroimaging and Risk Stratification

  1. MRI Vessel Wall Enhancement and MMD Outcomes

    • [DOI: 10.1007/S00330-023-10535-0]
      High-resolution MRI features were linked to clinical risk, potentially informing preoperative planning.

  2. Nomograms for Predicting Rebleeding and Outcomes

    • [DOI: 10.3171/2024.2.JNS232744]
      Well-validated clinical tools that integrate genetics and clinical features for long-term prognosis.

🧬 Pathophysiology and Comorbid Disease Connections

  1. Transcriptomics in MMD and SLE Crosstalk

    • [DOI: 10.3389/FIMMU.2024.1456392]
      A novel systems biology approach to uncover common pathways between MMD and autoimmune diseases like SLE.

  2. ZEB2 and Brain Microvascular Dysfunction Post-ICH

    • [DOI: 10.1080/15384101.2021.1959702]
      Delves into molecular mechanisms of endothelial dysfunction, bridging stroke and hemorrhage pathology.

📉 Risk Factors in Pediatric and Elderly Cohorts

  1. Preoperative Infarction & Pediatric Risk Factors

    • [DOI: 10.1007/S12975-023-01167-Z]
      Targeted focus on predictive markers in vulnerable pediatric populations.

  2. Outcomes in Elderly Post-Conservative vs. EDAS Treatment

  • [DOI: 10.3171/2023.7.JNS231060]
    Offers insights into age-specific management strategies and long-term care plans.

🔚 Conclusion

Prof. Qingbao Guo stands out as a dedicated neurosurgeon, educator, and researcher, committed to transforming patient outcomes through clinical expertise and scientific inquiry. His extensive training, hands-on experience, and impactful research make him a compelling candidate for any award celebrating excellence in medical and surgical innovation.